Method for preparing broad spectrum genetically engineered nano vaccine for malignant tumour

Abstract

The present invention method of malignant tumor broad-spectrum gene engineering nano vaccine adopts the following steps: adopting tumor specific common antigen gene melanin tumor antigen-I (MAGE-1) and biological immunoadjuvant heat shock protein 70(Hsp70) to make gene connection to form fusion gene (MAGE-1-Hsp70), utilizing colibacillus expression, separation and purification to obtain MAGE-1-Hsp70 fusion protein, and utilizing denaturation and renaturation to obtain fusion protein with high activity, combining said fusion protein and superantigen staphylococcal enterotoxin A to form complex antigenic compound; preparing nano liposome, covering the complex antigenic compound, utilizing molecular connection of N-hydroxysuccinimide ester and Hsp70 to form N-Hsp70, and inserting it into outer layer of nano liposome phospholipid membrane.

Description

technical field [0001] The invention belongs to applied genetic engineering technology, relates to a vaccine, in particular to a preparation method of a broad-spectrum genetic engineering nano-vaccine for malignant tumors. Background technique [0002] In my country, the incidence of malignant tumors ranks first in urban areas and second in rural areas, seriously threatening people's health and lives. The active immunotherapy of tumor patients with tumor vaccines can stimulate and enhance the immune rejection of tumors, which provides a new way for the treatment of tumors. In recent years, countries all over the world are actively developing tumor vaccines, and many tumor vaccines have entered clinical trials. Ideal, and MHC limitation, and for a long time, the tumor vaccine preparation process lacks the penetration and development of modern engineering technology (such as nanotechnology), resulting in some difficult problems, such as the targeting of vaccines, the effectiv...

AI Technical Summary

Problems solved by technology

In recent years, countries all over the world are actively developing tumor vaccines. Many tumor vaccines have entered clinical trials. Ideal, and MHC limitation, and for a long time, the tumor vaccine preparation process lacks the penetration and development of modern engineering technology (such as nanotechnology), resulting in some difficult problems, such as the targeting of vaccines, the effective presentation of antigens, Sustained-release issues for vaccines, etc. have yet to be resolved

Images